rvph20241205_8k.htm
false 0001742927 0001742927 2024-12-10 2024-12-10 0001742927 rvph:CommonStockParValue00001PerShareCustomMember 2024-12-10 2024-12-10 0001742927 rvph:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2024-12-10 2024-12-10
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 8-K
 
CURRENT REPORT
 
--12-31
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 10, 2024
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38634
85-4306526
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
10080 N Wolfe Road, Suite SW3-200, Cupertino, CA
  
95014
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (408) 501-8881
 
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
  
RVPH
  
Nasdaq Capital Market
Warrants to purchase one share of Common Stock
  
RVPHW
  
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.
 
As described under Proposal 5 of Item 5.07 of this Current Report on Form 8-K, on December 10, 2024, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at which, among other matters of business acted upon, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the Company’s authorized shares of common stock, par value $0.0001 per share (the “Common Stock”), from 115,000,000 to 315,000,000 (the “Certificate of Amendment”).
 
On December 10, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately. The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.
 
Item 5.07. Submission of Matters to a Vote of Security Holders.
 
On December 10, 2024, the Company held the Annual Meeting. The stockholders of the Company acted upon the following proposals at the Annual Meeting: (1) the election of directors, (2) the ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024, (3) the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers, (4) the vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation, and (5) the approval of the Certificate of Amendment to increase the Company’s authorized shares of Common Stock from 115,000,000 to 315,000,000 (“Proposal 5”). As there were sufficient votes at the time of the Annual Meeting to approve Proposal 5, Proposal 6 (as defined below) was unnecessary and such adjournment proposal was not submitted to the stockholders for approval at the Annual Meeting, as further described below.
 
The final voting results were as follows:
 
1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term. The votes were cast for this matter as follows:
 
           
Votes
    
Broker Non-
  
Nominees
    
Votes For
    
Withheld
    
Votes
  
Laxminarayan Bhat
    
6,877,403
    
4,896,145
    
10,762,193
  
Parag Saxena
    
6,861,061
    
4,912,487
    
10,762,193
  
Richard Margolin
    
6,938,763
    
4,834,785
    
10,762,193
  
Purav Patel
    
6,661,134
    
5,112,414
    
10,762,193
  
Les Funtleyder
    
6,949,314
    
4,824,234
    
10,762,193
  
 
2. The proposal to ratify the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024, was approved based upon the following votes:
 
Votes For
    
Votes Against
    
Abstentions
    
Broker Non-Votes
  
20,763,405
    
1,728,672
    
43,664
    
N/A
  
 
3. The proposal to approve, on an advisory basis, the executive compensation of the Company’s named executive officers was approved based upon the following votes:
 
Votes For
    
Votes Against
    
Abstentions
    
Broker Non-Votes
  
6,720,274
    
4,946,403
    
106,871
    
10,762,193
  
 
 
 
 
 
4. The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation:
 
One Year
  
Two Years
  
Three Years
  
Abstentions
  
Broker Non-Votes
  
7,112,520
  
600,244
  
847,253
  
3,213,531
  
10,762,193
  
 
The Board of Directors of the Company (the “Board”) has considered the outcome of this advisory vote on how often the Company will conduct an advisory vote on executive compensation and has determined, as was recommended with respect to this proposal by the Board in the Proxy Statement for the Annual Meeting, that the Company will conduct future advisory votes on executive compensation every year until the occurrence of the next vote on how often the Company will conduct an advisory vote on executive compensation. The next vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation is required to occur no later than the Company’s 2030 Annual Meeting of Stockholders.
 
5. The proposal to approve the Certificate of Amendment to increase the Company’s authorized shares of Common Stock from 115,000,000 to 315,000,000 was approved based upon the following votes:
 
Votes For
    
Votes Against
    
Abstentions
    
Broker Non-Votes
  
15,559,792
    
6,654,265
    
321,684
    
N/A
  
 
6. In connection with the Annual Meeting, the Company also solicited proxies with respect to a proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of Proposal 5 were insufficient to approve Proposal 5 (“Proposal 6”).
 
As there were sufficient votes at the time of the Annual Meeting to approve Proposal 5, Proposal 6 was unnecessary and such proposal was not submitted to the stockholders for approval at the Annual Meeting.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit Number
  
Description
3.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
  
       
Date: December 12, 2024
By:
/s/ Narayan Prabhu
  
   
Narayan Prabhu
  
   
Chief Financial Officer
  
 
 

Exhibit 3.1

ex31.jpg

 
 

 

CERTIFICATE OF AMENDMENT OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

REVIVA PHARMACEUTICALS HOLDINGS, INC.

A Delaware Corporation

 

Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Reviva Pharmaceuticals Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

 

 

1.

The name of the Corporation is Reviva Pharmaceuticals Holdings, Inc. The Corporation was incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 11, 2020 (as further amended and restated, the “Certificate of Incorporation”).

 

 

2.

The Certificate of Incorporation is hereby amended to increase the authorized shares of the Corporation’s common stock, par value $0.0001 per share, by deleting the first paragraph under Section A of Article IV, and replacing such paragraph with the following:

 

“The total number of shares of capital stock which the Corporation shall have authority to issue is Three Hundred Twenty Five Million (325,000,000), of which (i) Three Hundred Fifteen Million (315,000,000) shares shall be a class designated as common stock, par value $0.0001 per share (the “Common Stock”), and (ii) Ten Million (10,000,000) shares shall be a class designated as preferred stock, par value $0.0001 per share (the “Preferred Stock”).”

 

 

3.

The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Certificate of Incorporation and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law of the State of Delaware.

 

 

4.

All other provisions of the Certificate of Incorporation shall remain in full force and effect.

 

 

5.

This Certificate of Amendment and the amendment to the Certificate of Incorporation effected hereby shall be effective immediately upon filing.

 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 10th day of December, 2024.

 

 

REVIVA PHARMACEUTICALS HOLDINGS, INC.
   
 

By:

/s/ Laxminarayan Bhat

 

Name:

Laxminarayan Bhat
 

Title:

Chief Executive Officer